FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2611393721> ?p ?o ?g. }

• W2611393721 endingPage "1554" @default.
• W2611393721 startingPage "1546" @default.
• W2611393721 abstract "To analyse the effects of patient characteristics and different oral antidiabetes drug (OAD) use on standardised clinical outcomes in type 2 diabetes patients initiating insulin glargine 100 U/mL (Gla-100).Patient-level data from 16 randomized, treat-to-target clinical trials that added Gla-100 to existing metformin (MET), sulfonylurea (SU) or metformin plus sulfonylurea (MET+SU) treatment in insulin-naïve patients inadequately controlled by oral therapy were analysed and patients were followed for ≥24 weeks. Change in glycated haemoglobin A1c (HbA1c) from baseline to week 24, other glycaemic endpoints and incidence of hypoglycaemia (overall, nocturnal, and severe) were analysed by age (<65 vs ≥65 years), gender (male vs female), body mass index (BMI; <25 vs ≥25 to <30 vs >30 kg/m2 ) and concomitant OAD (MET vs SU vs MET+SU).At baseline, the overall population (N = 3188) had a mean age of 57.7 years, BMI of 30.5 kg/m2 , HbA1c of 8.7%, fasting plasma glucose of 192 mg/dL, and 52.7% were male. Younger and older patients had similar HbA1c reductions with Gla-100 and a similar risk of hypoglycaemia. Females and patients with BMI <25 kg/m2 were less likely to achieve HbA1c targets and more likely to experience hypoglycaemia, regardless of concomitant OAD. Adding Gla-100 to SU therapy (alone or in combination with MET) increased hypoglycaemia risk across all analyses.Our data suggest that female patients with type 2 diabetes and normal-weight patients treated with Gla-100 and MET ± SU are less likely to achieve glycaemic targets and, therefore, may require more clinical attention. Addition of Gla-100 to SU regimens may increase hypoglycaemia risk irrespective of age, gender, or BMI." @default.
• W2611393721 created "2017-05-12" @default.
• W2611393721 creator A5003557683 @default.
• W2611393721 creator A5025169113 @default.
• W2611393721 creator A5039452695 @default.
• W2611393721 creator A5051095182 @default.
• W2611393721 creator A5057048949 @default.
• W2611393721 creator A5057323309 @default.
• W2611393721 creator A5058274800 @default.
• W2611393721 creator A5078134786 @default.
• W2611393721 date "2017-07-27" @default.
• W2611393721 modified "2023-10-16" @default.
• W2611393721 title "Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes" @default.
• W2611393721 cites W1165574736 @default.
• W2611393721 cites W134853810 @default.
• W2611393721 cites W1888036258 @default.
• W2611393721 cites W1967748312 @default.
• W2611393721 cites W1971329074 @default.
• W2611393721 cites W1984434976 @default.
• W2611393721 cites W1987070403 @default.
• W2611393721 cites W2005778725 @default.
• W2611393721 cites W2024618354 @default.
• W2611393721 cites W2050249722 @default.
• W2611393721 cites W2059616065 @default.
• W2611393721 cites W2062014697 @default.
• W2611393721 cites W2063423309 @default.
• W2611393721 cites W2102561025 @default.
• W2611393721 cites W2104113021 @default.
• W2611393721 cites W2111102514 @default.
• W2611393721 cites W2121414237 @default.
• W2611393721 cites W2122130517 @default.
• W2611393721 cites W2122596924 @default.
• W2611393721 cites W2122994980 @default.
• W2611393721 cites W2126781806 @default.
• W2611393721 cites W2126838326 @default.
• W2611393721 cites W2131954113 @default.
• W2611393721 cites W2146563690 @default.
• W2611393721 cites W2160088494 @default.
• W2611393721 cites W2163457223 @default.
• W2611393721 cites W2171876128 @default.
• W2611393721 cites W2172193326 @default.
• W2611393721 cites W2280616855 @default.
• W2611393721 cites W4239837977 @default.
• W2611393721 cites W570726985 @default.
• W2611393721 doi "https://doi.org/10.1111/dom.12966" @default.
• W2611393721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28449412" @default.
• W2611393721 hasPublicationYear "2017" @default.
• W2611393721 type Work @default.
• W2611393721 sameAs 2611393721 @default.
• W2611393721 citedByCount "7" @default.
• W2611393721 countsByYear W26113937212018 @default.
• W2611393721 countsByYear W26113937212019 @default.
• W2611393721 countsByYear W26113937212020 @default.
• W2611393721 countsByYear W26113937212021 @default.
• W2611393721 countsByYear W26113937212023 @default.
• W2611393721 crossrefType "journal-article" @default.
• W2611393721 hasAuthorship W2611393721A5003557683 @default.
• W2611393721 hasAuthorship W2611393721A5025169113 @default.
• W2611393721 hasAuthorship W2611393721A5039452695 @default.
• W2611393721 hasAuthorship W2611393721A5051095182 @default.
• W2611393721 hasAuthorship W2611393721A5057048949 @default.
• W2611393721 hasAuthorship W2611393721A5057323309 @default.
• W2611393721 hasAuthorship W2611393721A5058274800 @default.
• W2611393721 hasAuthorship W2611393721A5078134786 @default.
• W2611393721 hasBestOaLocation W26113937212 @default.
• W2611393721 hasConcept C126322002 @default.
• W2611393721 hasConcept C134018914 @default.
• W2611393721 hasConcept C2777180221 @default.
• W2611393721 hasConcept C2778854520 @default.
• W2611393721 hasConcept C2779306644 @default.
• W2611393721 hasConcept C2779384505 @default.
• W2611393721 hasConcept C2779920387 @default.
• W2611393721 hasConcept C2780221984 @default.
• W2611393721 hasConcept C2780323712 @default.
• W2611393721 hasConcept C2780668416 @default.
• W2611393721 hasConcept C2908647359 @default.
• W2611393721 hasConcept C555293320 @default.
• W2611393721 hasConcept C71924100 @default.
• W2611393721 hasConcept C99454951 @default.
• W2611393721 hasConceptScore W2611393721C126322002 @default.
• W2611393721 hasConceptScore W2611393721C134018914 @default.
• W2611393721 hasConceptScore W2611393721C2777180221 @default.
• W2611393721 hasConceptScore W2611393721C2778854520 @default.
• W2611393721 hasConceptScore W2611393721C2779306644 @default.
• W2611393721 hasConceptScore W2611393721C2779384505 @default.
• W2611393721 hasConceptScore W2611393721C2779920387 @default.
• W2611393721 hasConceptScore W2611393721C2780221984 @default.
• W2611393721 hasConceptScore W2611393721C2780323712 @default.
• W2611393721 hasConceptScore W2611393721C2780668416 @default.
• W2611393721 hasConceptScore W2611393721C2908647359 @default.
• W2611393721 hasConceptScore W2611393721C555293320 @default.
• W2611393721 hasConceptScore W2611393721C71924100 @default.
• W2611393721 hasConceptScore W2611393721C99454951 @default.
• W2611393721 hasFunder F4320307781 @default.
• W2611393721 hasIssue "11" @default.
• W2611393721 hasLocation W26113937211 @default.
• W2611393721 hasLocation W26113937212 @default.
• W2611393721 hasLocation W26113937213 @default.

• next